Physician profile
Eugene Speck
NPI 1982693198
$1,380.35
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $735 · 2021: $83.27 · 2023: $20.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $509.68 | 2019-2020 | |
| Allergan, INC. | $424.16 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $99.08 | 2019-2020 | |
| Melinta Therapeutics, LLC | $66.81 | 2019-2020 | |
| Viiv Healthcare Company | $58.76 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $50.70 | 2019-2021 | |
| Gilead Sciences, INC. | $43.50 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $38.50 | 2019-2020 | |
| Abbvie INC. | $30.42 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $18.40 | 2020 | |
| Insmed, INC. | $15.06 | 2020 | |
| Biomerieux INC | $13.64 | 2019 | |
| Theratechnologies INC. | $11.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Speck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.